Mitochondrial medicine focus drives NeuroVive orphan ambitions

Underpinned by a profound understanding of genetic mitochondrial disorders, Swedish biotech NeuroVive Pharmaceutical AB is pursuing a two-pronged orphan and speciality pharma approach. CEO Erik Kinnman spoke with Scrip’s Mike Ward and explained how the company is looking for partners for its NASH and hepatocellular cancer programs but intends to develop its own orphan treatments.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Erik Kinnman – CEO, NeuroVive Pharmaceutical